RT Journal Article
SR Electronic
T1 Integrative proteogenomic analyses provide novel interpretations of type 1 diabetes risk loci through circulating proteins
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.19.23300201
DO 10.1101/2023.12.19.23300201
A1 Lu, Tianyuan
A1 Manousaki, Despoina
A1 Sun, Lei
A1 Paterson, Andrew D.
YR 2023
UL http://medrxiv.org/content/early/2023/12/19/2023.12.19.23300201.abstract
AB Type 1 diabetes (T1D) requires new preventive measures and interventions. Circulating proteins are promising biomarkers and drug targets. Leveraging genome-wide association studies (GWASs) of T1D (18,942 cases and 501,638 controls) and circulating protein abundances (10,708 individuals), the associations between 1,565 circulating proteins and T1D risk were assessed through Mendelian randomization, followed by multiple sensitivity and colocalization analyses, examinations of horizontal pleiotropy, and replications. Genetically increased circulating abundances of CTSH, IL27RA, SIRPG, and PGM1 were associated with an increased risk of T1D, consistently replicated in other cohorts. Bulk tissue and single-cell gene expression profiles revealed strong enrichment of CTSH, IL27RA, and SIRPG in immune system-related tissues, and PGM1 in muscle and liver tissues. Among immune cells, CTSH was enriched in B cells and myeloid cells, while SIRPG was enriched in T cells and natural killer cells. These proteins warrant exploration as T1D biomarkers or drug targets in relevant tissues.Competing Interest StatementT.L. was employed by 5 Prime Sciences Inc. until Sept 2023. The research presented in this paper was conducted independently, and 5 Prime Sciences Inc. was not involved in the design, execution, analysis, or interpretation of the study. T.L. declares no ongoing conflicts of interest. The other authors declare no conflicts of interest.Funding StatementT.L. has been supported by a Schmidt AI in Science Postdoctoral Fellowship. The funder has no role in study design; collection, management, analysis and interpretation of data; or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes